Eftozanermin alfa
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Eftozanermin alfa, covering 2025-05-16 to 2025-05-16. Get the full timeline:
Most recent: Clinical Trial Update: Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]